Gyre Therapeutics, Inc. (GYRE)
4.555
-1.86
(-28.94%)
USD |
NASDAQ |
Oct 30, 16:00
4.64
+0.08
(+1.87%)
After-Hours: 20:00
Gyre Therapeutics Net Income (Quarterly) : -14.27M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -14.27M |
| March 31, 2026 | -9.858M |
| December 31, 2025 | -1.366M |
| September 30, 2025 | 5.936M |
| June 30, 2025 | -2.237M |
| March 31, 2025 | 3.734M |
| December 31, 2024 | 0.569M |
| September 30, 2024 | 2.856M |
| June 30, 2024 | 4.538M |
| March 31, 2024 | 9.935M |
| December 31, 2023 | -81.69M |
| September 30, 2023 | 7.51M |
| June 30, 2023 | 3.77M |
| March 31, 2023 | 4.217M |
| December 31, 2022 | -40.45M |
| September 30, 2022 | -4.884M |
| June 30, 2022 | 51.63M |
| March 31, 2022 | -14.54M |
| December 31, 2021 | -20.33M |
| September 30, 2021 | -25.24M |
| June 30, 2021 | -19.93M |
| March 31, 2021 | -22.44M |
| December 31, 2020 | -18.91M |
| September 30, 2020 | -16.03M |
| June 30, 2020 | -17.25M |
| Date | Value |
|---|---|
| March 31, 2020 | -4.053M |
| December 31, 2019 | -13.61M |
| September 30, 2019 | -12.71M |
| June 30, 2019 | -13.78M |
| March 31, 2019 | -15.08M |
| December 31, 2018 | -10.84M |
| September 30, 2018 | -7.694M |
| June 30, 2018 | -6.482M |
| March 31, 2018 | -5.042M |
| December 31, 2017 | -5.753M |
| September 30, 2017 | -5.793M |
| June 30, 2017 | -5.877M |
| March 31, 2017 | -4.138M |
| December 31, 2016 | -3.75M |
| September 30, 2016 | -4.771M |
| June 30, 2016 | -4.833M |
| March 31, 2016 | -3.592M |
| December 31, 2015 | -5.13M |
| September 30, 2015 | -5.051M |
| June 30, 2015 | -1.724M |
| March 31, 2015 | -2.858M |
| December 31, 2014 | -1.302M |
| September 30, 2014 | -1.502M |
| June 30, 2014 | -8.136M |
| March 31, 2014 | -15.00M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Cytokinetics, Inc. | -198.76M |
| Incyte Corp. | -784.80M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | 3.309M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 29.10M |
| Total Expenses (Quarterly) | 39.71M |
| EPS Diluted (Quarterly) | -0.1159 |
| Enterprise Value | 468.60M |
| Gross Profit Margin (Quarterly) | 92.41% |
| Profit Margin (Quarterly) | -49.03% |
| Earnings Yield | -4.30% |
| Normalized Earnings Yield | -3.873 |